Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 5/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7505158 | 0.89 | NOTUM (0.37) | NOTUMMAPTSCN5ATOP2ATOP2B | |
| SCHEMBL8563762 | 0.86 | KCNH2 (0.36) | NOTUMMAPTSCN5ATOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL7504444 | 0.85 | KCNH2 (0.35) | NOTUMMAPTSCN5ATOP2ATOP2B | |
| SCHEMBL14515902 | 0.85 | SCN5A (0.40) | NOTUMSCN5AKDM4EKCNH2HRH3 | |
| SCHEMBL20960262 | 0.84 | TOP2A (0.38) | NOTUMTOP2ATOP2BKDM4ESMN1; SMN2 | |
| SCHEMBL5241608 | 0.84 | NOTUM (0.36) | NOTUMSCN5ATOP2ATOP2BKDM4E | |
| SCHEMBL8566201 | 0.83 | KDM4E (0.43) | SCN5ATOP2AKDM4EKCNH2HRH3 | |
| Hydrochloric Acid SCHEMBL8567838 | 0.83 | KDM4E (0.40) | NOTUMSCN5AKDM4EKCNH2RORC | |
| SCHEMBL8565386 | 0.83 | SCN5A (0.41) | NOTUMSCN5ATOP2ATOP2BKCNH2 | |
| SCHEMBL12502227 | 0.83 | TOP2A (0.45) | NOTUMTOP2ATOP2BKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | NOTUM 4466/4885MAPT 3833/4885SCN5A 355/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | NOTUM 4466/4885MAPT 3833/4885SCN5A 355/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | NOTUM 4466/4885MAPT 3833/4885SCN5A 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.